Linda Burkly - Editas Medicine Executive Officer
| EDIT Stock | USD 2.24 0.04 1.82% |
Executive
Linda Burkly is Executive Officer of Editas Medicine
| Age | 67 |
| Address | 11 Hurley Street, Cambridge, MA, United States, 02141 |
| Phone | 617 401 9000 |
| Web | https://www.editasmedicine.com |
Latest Insider Transactions
Linda Burkly Latest Insider Activity
Tracking and analyzing the buying and selling activities of Linda Burkly against Editas Medicine stock is an integral part of due diligence when investing in Editas Medicine. Linda Burkly insider activity provides valuable insight into whether Editas Medicine is net buyers or sellers over its current business cycle. Note, Editas Medicine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Editas Medicine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Linda Burkly over three months ago Disposition of 11886 shares by Linda Burkly of Editas Medicine at 5.4156 subject to Rule 16b-3 |
Editas Medicine Management Efficiency
The company has return on total asset (ROA) of (0.3432) % which means that it has lost $0.3432 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7856) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nina Devlin | Vertex Pharmaceuticals | N/A | |
| Samarth Kulkarni | Crispr Therapeutics AG | 46 | |
| Daniel Anderson | Crispr Therapeutics AG | N/A | |
| Sonja MD | Sana Biotechnology | 49 | |
| John MD | Sana Biotechnology | N/A | |
| Ryan Fischesser | Caribou Biosciences | N/A | |
| Manmohan Singh | Beam Therapeutics | N/A | |
| Yuko JD | Sana Biotechnology | N/A | |
| Kristen CPA | Vertex Pharmaceuticals | 47 | |
| Joaquim Marques | Ginkgo Bioworks Holdings | N/A | |
| Reigin Zawadzki | Caribou Biosciences | N/A | |
| Jonathan JD | Vertex Pharmaceuticals | 60 | |
| Steven CPA | Ginkgo Bioworks Holdings | N/A | |
| Richard Mulligan | Sana Biotechnology | 69 | |
| Allan MD | Prime Medicine, Common | 49 | |
| Eric Schmidt | Allogene Therapeutics | 54 | |
| Amy CFA | Caribou Biosciences | N/A | |
| Julianne MBA | Crispr Therapeutics AG | N/A | |
| Christian MBA | Sana Biotechnology | 41 | |
| JD Esq | Caribou Biosciences | 69 | |
| MD FACP | Crispr Therapeutics AG | 50 | |
Management Performance
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 |
Editas Medicine Leadership Team
Elected by the shareholders, the Editas Medicine's board of directors comprises two types of representatives: Editas Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Editas. The board's role is to monitor Editas Medicine's management team and ensure that shareholders' interests are well served. Editas Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Editas Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilmore MD, CEO President | ||
| Bruce Eaton, Exec Officer | ||
| Gilmore ONeill, CEO President | ||
| Cristi Barnett, Corporate Relations | ||
| Charlene JD, Executive Counsel | ||
| James Mullen, Chairman of the Board | ||
| Michelle Robertson, Principal CFO | ||
| David Liu, CoFounder Member | ||
| Caren Deardorf, Executive Officer | ||
| Pr Church, CoFounder Member | ||
| Harry III, VP Operations | ||
| Mark Shearman, Ex Officer | ||
| Feng Zhang, CoFounder Member | ||
| Baisong MD, Executive Officer | ||
| Linea Aspesi, Executive Officer | ||
| Linda Burkly, Executive Officer | ||
| CPA CFA, CFO VP | ||
| George Church, CoFounder Member | ||
| Gregory Whitehead, Executive Officer |
Editas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Editas Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (41.69 M) | ||||
| Shares Outstanding | 82.55 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 70.13 % | ||||
| Number Of Shares Shorted | 15.91 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 1.05 X | ||||
| Price To Sales | 2.99 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.